Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 405-411

  Hardy, Isabelle ^a   Brenner, Bluma ^b   Quashie, Peter ^b   Thomas, Réjean ^c   Petropoulos, Christos ^d   Huang, Wei ^d   Moisi, Daniela ^b   Wainberg, Mark A ^b   Roger, Michel ^a,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Clinique Medicale l'Actuel   (Canada)

^d MONOGRAM BIOSCIENCES   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Genotype; HIV 1; Integrase inhibitors; Mutations; Phenotype

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIGEN P24; ATAZANAVIR; DARUNAVIR; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; INTEGRASE; INTEGRASE INHIBITOR; PROTEIN BINDING;

AMINO ACID SEQUENCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS RESISTANCE; DRUG BINDING; DRUG TREATMENT FAILURE; ELECTROCHEMISTRY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; IC50; MEDICAL HISTORY; MOLECULAR DOCKING; MOLECULAR EVOLUTION; MOLECULAR MODEL; PHENOTYPE; SPUMA VIRUS; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; ENZYME ACTIVE SITE; EVOLUTION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; MUTATION; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BINDING SITES; BIOLOGICAL EVOLUTION; CATALYTIC DOMAIN; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; GENOTYPE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PHENOTYPE; PROTEIN BINDING; VIRAL LOAD;

EID: 84922448572     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku387     Document Type: Article

References (24)

1. Blanco JL, Varghese V, Rhee SY et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203: 1204-14.
2. Mesplede T, Quashie PK,Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS 2012; 7: 401-8.
3. Quashie PK, Mesplede T,Wainberg MA. Evolution of HIV integrase resistance mutations. Curr Opin Infec Dis 2013; 26: 43-9.
4. Hare S, Smith SJ, Metifiot M et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmcol 2011; 80: 565-72.
5. Kobayashi M, Yoshinaga T, Seki Tet al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
6. Quashie PK, Mesplede T, Han YS et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
7. Underwood MR, Johns BA, Sato A et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravirtreated adults. J Acquir Immune Defic Syndr 2012; 61: 297-301.
8. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the Phase III VIKING-3 Study. J Infect Dis 2014; 210: 354-62.
9. Brenner BG, Lowe M, Moisi D et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol 2011; 83: 751-9.
10. Brenner BG, Roger M, Stephens D et al. Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis 2011; 204: 1115-9.
11. Quashie PK, Mesplede T, Han YS et al. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 2013; 57: 6223-35.
12. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008; 9: 40.
13. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31: 455-61.
14. Morris GM, Huey R, LindstromWet al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009; 30: 2785-91.
15. Hare S, Vos AM, Clayton RF et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010; 107: 20057-62.
16. Hare S, Maertens GN, Cherepanov P. 3'-Processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J 2012; 31: 3020-8.
17. Nichols G, Mills A, Grossberg R et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3 [Abstract from the Eleventh International Congress on Drug Therapy in HIV infection]. J Int AIDS Soc 2012; 15: 18112.
18. Vavro C, Hasan S, Madsen H et al. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 2013; 57: 1379-84.
19. Eron JJ, Clotet B, Durant J et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207: 740-8.
20. Margot NA, Hluhanich RM, Jones GS et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antivir Res 2012; 93: 288-96.
21. Reigadas S, Masquelier B, Calmels C et al. Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A. Antimicrob Agents Chemother 2011; 55: 3187-94.
22. Collins DW, Jukes TH. Rates of transition and transversion in coding sequences since the human-rodent divergence. Genomics 1994; 20: 386-96.
23. Aguiar RS, Peterlin BM. APOBEC3 proteins and reverse transcription. Virus Res 2008; 134: 74-85.
24. Garel JR. Evidence for involvement of proline cis-trans isomerization in the slow unfolding reaction of RNase A. Proc Natl Acad Sci USA 1980; 77: 795-8.